Association Between Use of Sodium–Glucose Cotransporter 2 Inhibitors and Epilepsy: A Population-Based Study Using Target Trial Emulation
Main finding · Incident epilepsyResult — go to the resultHazard ratio 0.71 95% CI 0.52–0.97Authors' conclusion
SGLT-2is were associated with a reduced incidence of epilepsy in the study population. More studies are needed to confirm and replicate the study results.
Study context
- Population
- Patients with T2D who were new users of an SGLT2i or a DPP-4i, Yinzhou Regional Health Care Database
- Participants
- 24,930 vs 28,924
- Exposure
- SGLT2i vs DPP-4i
- SGLT-2isn = 24,930
- DPP-4isn = 28,924reference
- Outcome
- Incidence of epilepsy
- Follow-up
- Median 2.0 (IQR 0.8-3.3) years
Methodological detailsnew-user design, inverse probability of treatment weighting
- New-user design
- Inverse probability of treatment weighting
Main finding
Incident epilepsy
Hazard ratio
0.71
95% CI 0.52–0.97
By group
SGLT-2is
174.2 per 100,000 person-years
DPP-4is
231.5 per 100,000 person-years
SGLT-2isvs DPP-4is
HR 0.71 (95% CI 0.52–0.97)
As reported in the abstract
- Patients with incident epilepsy, total
- 243
Observational data: associations, not effects.
Further findings
- Various subgroup and sensitivity analyses supported the primary results
Original publication
Association Between Use of Sodium–Glucose Cotransporter 2 Inhibitors and Epilepsy: A Population-Based Study Using Target Trial Emulation. Diabetes Care. Published 25 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →